• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency

27/11/2017 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

The views expressed in this article are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this forum, which remain solely the responsibility of their authors.

Reprinted with permission. For the full original post, see the Medicines Law & Policy blog.

By Ellen ‘t Hoen

The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing.

Pharmacy scale

He specifically told the Dutch parliament that he plans to “extensively explore” the use of compulsory licensing of patents of medicines that are too expensive. (See here for media coverage in Dutch). Compulsory licensing lifts the monopoly effect of a patent by allowing others to produce generic versions. The Dutch patent law provides for compulsory licensing, including for reasons of public interest, which presumably covers addressing “absurd pricing” of needed medicines.  EU medicines regulations may stand in the way of the Minister’s plans when data exclusivity rules prevent the registration of the generic. For a detailed discussion of the need to ensure coherence in EU law on this matter see our paper here. He will also explore if he can authorise pharmacists to prepare medicines al lower cost for individual patients.

The Minister follows the recommendations of the Netherlands Council for Public Health and Society, an official government advisory body, which published its report on eight November. The Council’s report – Development of new medicines: Better, faster, cheaper – outlines a number of actions the Dutch government can take to immediately address high drug pricing, including the use of compulsory licensing to strengthen the government’s position in price negotiations.

The new Dutch government and the opposition seem to be aligned with each other on the need to take firm action to ensure access to new and expensive medicines. On 21 November three opposition parties presented their report on the pharmaceutical industry in which they recommend a series of measures aimed at lowering the price of medicines:

  • A ban on the endless extension (evergreening) of patents.
  • A National Medicines Research Fund, for independent medical research. Research priorities are determined by the government and not by the pharmaceutical companies.
  • Preventing conflicts of interest between doctor and big pharma by restricting aggressive marketing and actively enforcing the advertising ban.
  • Use of compulsory licenses as pharmaceutical companies refuse to lower absurdly high prices.
  • Adaptation of the competition law and stricter supervision to better combat abuse of power
  • Put an end to none transparent price negotiations.

…

Some commentators last week also warned that the firm stance from the Netherlands on high medicines pricing may jeopardize its chances of becoming the new home of the European Medicines Agency (EMA). The EMA has to leave London because of Brexit. Apparently, the Dutch plans to tackle high medicines pricing has had no such effect. In the same week, the EU Member States decided that the EMA would move to Amsterdam where it will continue its operations in March 2019 at the latest.

Read the full post on the Medicines Law & Policy blog.

 

Image Credits: Medicines Law & Policy

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Europe, Finance, Health & IP, Health Policy Watch, Human Rights, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

Trackbacks

  1. La Actualidad  en relación con las Licencias Obligatorias sobre Patentes | Arsenal Terapéutico says:
    03/03/2018 at 9:37 pm

    […] en los Países Bajos, el ministro de sanidad Bruno Bruins, que tomó posesión de su cargo el pasado mes de noviembre ha hecho varias declaraciones en las […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.